More threads by Halo

Halo

Member
New ADHD Drugs Reduce Likelihood of Abuse

Tuesday, May 29, 2007
By Karla Gale

NEW YORK (Reuters Health) - Two new formulations of drugs traditionally used to treat attention deficit/hyperactivity disorder (ADHD), methylphenidate and d-amphetamine, last longer and have less potential for abuse, according to presentations at the American Psychiatric Association annual meeting in San Diego.

"Daytrana and Vyvanse are new options that address the limitations of medications previously available to treat ADHD," Dr. Robert L. Findling, from Case Western Reserve University in Cleveland, told Reuters Health.

Findling presented his teams' research findings on the drugs, both marketed by Shire US Inc., and approved by the US Food and Drug Administration.

Daytrana delivers methylphenidate through a skin patch with the dosage controlled by the patch size and by the duration of wear. "One advantage of the patch, first and foremost, is its flexibility," Findling said.

"Kids have no difficulty using the patch," he added, and it has been formulated so it can't be re-used. "That way, they can't stick it on a buddy" when they're horsing around, he added.

Findling's team compared the patch with oral methylphenidate and placebo in 270 patients ages 6 to 12 years old. The study included a 5-week initial treatment phase, followed by a 2-week maintenance phase, and a 30-day follow-up period.

Using an ADHD rating scale, scores with both forms of the drug improved ADHD symptoms compared with placebo; and both were equally effective, according to the investigators.

Findling and associates also presented the trial results for Vyvanse (lisdexamfetamine dimesylate), a drug associated with d-amphetamine. It offers the advantage of extended duration consistently delivered throughout the day, with a reduced potential for abuse, overdose toxicity and drug tampering, the investigators reported.

They investigated the long-term efficacy, safety, and tolerability in patients between 6 and 12 years old. The optimum dose was 30 to 70 milligrams per day.

At the end of the 12-month trial, treatment resulted in a 60-percent improvement in ADHD scores. Using another rating scale, 95 percent of subjects were considered "much improved" or "very much improved" at 12 months.

For both drugs, adverse effects were mostly mild-to-moderate, similar to those of the parent drugs, d-amphetamine and methylphenidate, the presenters noted.
 

Similar threads

David, Spot on with this comment, a point covered in my book New ADHD Medication Rules - Brain Science & Common Sense in some detail with indications and specific how-to. Also on this link page is a a summary of the multiple problems with ADHD meds linked here if you want to simply see the SlideShare review on ADHD Med Problems: New ADHD Medication Rules. Happy Holidays... and David, if you would like a review copy send me a note offline and I'll shoot you a copy for your review. Thanks! Chuck
Replies
1
Views
2K
This strikes me as "medical research" (quotes inentional to imply sarcasm) of the worst and most irresponsible kind. 1. Retrospective reports of impressions of bereaved parents years after the loss of a child? 2. 10 out of 564 children (1.8%) compared with 2 out of 564 children (0.4%)? Doesn't that mean that 98.2% of the children taking stimulants did NOT have strokes or heart attacks? How many ADHD children taking stimulants are still alive and healthy 50 or 60 years later? How many...
Replies
1
Views
1K
ADHD drugs not linked to future drug abuse Tues., April. 1, 2008 Study finds Ritalin, other stimulants, don't boost risks of later addiction WASHINGTON - Using stimulants like Ritalin to treat attention-deficit hyperactivity disorder in children, particularly younger ones, does not seem to boost the risk of later substance abuse, researchers said on Tuesday. There has been a debate over whether such medications are the best way to treat ADHD, a condition marked by inattention...
Replies
0
Views
2K
Study of young adults finds no link between stimulant treatment and alcohol, drug use ADHD Drugs Won't Raise Risk of Substance Abuse SATURDAY, March 1 (HealthDay News) -- Parents of children who are prescribed psychostimulants for attention deficit-hyperactivity disorder (ADHD) might have one less thing to worry about now that a new study concludes these kids are no more likely than their peers to abuse drugs and alcohol as young adults. The report, which was funded by the National...
Replies
0
Views
1K
U.S. guide helps parents make decisions on ADHD drugs Tue Oct 2, 2007 By Julie Steenhuysen CHICAGO (Reuters) - When the diagnosis is attention deficit/hyperactivity disorder, the question most parents face is: To medicate or not to medicate? A new parents' guide to ADHD drugs, released on Tuesday by the American Academy of Child and Adolescent Psychiatry and the American Psychiatric Association, may offer some help. It comes in the wake of recent warnings by U.S. regulators about...
Replies
0
Views
2K
Top